{"id":"imm01","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for IMM01 are limited in public literature, the drug appears to be developed as an immuno-oncology therapeutic by ImmuneOnco Biopharmaceuticals. Given the company's focus and the phase 3 status, it likely targets immune checkpoints or enhances T-cell mediated tumor killing, though the exact molecular target requires confirmation from clinical trial data.","oneSentence":"IMM01 is an immunotherapeutic agent designed to enhance anti-tumor immune responses, likely through modulation of immune checkpoint pathways or T-cell activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:35.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06784297","phase":"","title":"INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Immunis, Inc.","startDate":"","conditions":"Sarcopenia, Obesity and Obesity-related Medical Conditions","enrollment":""},{"nctId":"NCT06600581","phase":"PHASE2","title":"Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immunis, Inc.","startDate":"2024-12-19","conditions":"Muscle Performance, Sarcopenic Obesity","enrollment":55},{"nctId":"NCT06647862","phase":"PHASE3","title":"IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)","status":"RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2024-11-11","conditions":"Chronic Myelomonocytic Leukemia","enrollment":170},{"nctId":"NCT05211986","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.","status":"RECRUITING","sponsor":"Immunis, Inc.","startDate":"2022-09-13","conditions":"Muscle Atrophy","enrollment":28},{"nctId":"NCT07170787","phase":"PHASE1, PHASE2","title":"A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2025-10-15","conditions":"Advanced Solid Tumors","enrollment":104},{"nctId":"NCT06465446","phase":"PHASE3","title":"A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2024-06","conditions":"Classic Hodgkin Lymphoma","enrollment":202},{"nctId":"NCT05140811","phase":"PHASE1, PHASE2","title":"A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2022-01-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":126},{"nctId":"NCT05860075","phase":"PHASE1","title":"Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy","status":"TERMINATED","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2019-11-19","conditions":"Hematologic Malignancy","enrollment":73},{"nctId":"NCT05833984","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas","status":"UNKNOWN","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2022-05-17","conditions":"Solid Tumor, Classic Hodgkin Lymphoma","enrollment":309}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMM01 Ingection","SIRPα Fc","Timdarpacept","IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG1 fusion protein"],"phase":"phase_3","status":"active","brandName":"IMM01","genericName":"IMM01","companyName":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","companyId":"immuneonco-biopharmaceuticals-shanghai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}